AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02918513 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Element 4 - Social Connectedness
Description: 4. Daily wellness element focusing on Social Connectedness; adherence documented online daily
Study NCT02918513 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Element 5 - Nutrition
Description: 5. Daily wellness element focusing on Nutrition; adherence documented online daily
Study NCT02918513 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Element 6 - Wellness Exercises
Description: 6. Daily wellness workbook exercises focusing on improving mental wellness; adherence documented online daily
Study NCT02918513 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Element 7 - Motivational Messages
Description: 7. Daily motivational emails offering information on one of the 5 wellness elements each day (Exercise, Mindfulness Meditation, Sleep, Social Connectedness, and Nutrition)
Study NCT00464776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Study NCT06284135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Michl-stitch
Description: In the intervention group, a ventral fixation was performed by suturing the ventral bladder peritoneum to the plexus Santorini and from there to the right and left lateral endopelvic fascia (MICHL-stitch).
Study NCT01558648 — intervention group
Intervention type: BEHAVIORAL
Intervention: Quality of Life instruments, FACT-E, Symptom Assessment Scale, Brief Pain Inventory and Daily Analgesic Log
Description: Initial pre-operative assessment post-operative assessment in-hospital assessment at first post-operative visit (clinic visits, or by telephone or mail) assessments at 4, 8, 12, 18, and 24 months post-operatively (+/- 2 month window). For patients who have their surgery delayed, they may be asked to complete another, more updated set of pre-surgery surveys. For the dysphagia score and CT Scan vs EUS subset will be a dysphagia questionnaire, administered at the time of the initial clinic visit.
Study NCT04337918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NORS (Nitric Oxide Releasing Solution)
Description: NORS treatment will consist of daily self-administration of three routes; Nitric Oxide Gargle (NOG) every morning, Nitric Oxide Nasophyaryngeal Irrigation (NONI) every evening, and Nitric Oxide Nasal Spray (NONS) up to 5 times per day.
Study NCT04337918 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: NORS (Nitric Oxide Releasing Solution)
Description: Up to ten volunteers who are found to be COVID-19 positive during screening will be eligible to enroll in the 21-day Treatment sub-study and receive daily NORS treatment for 14 days. NORS treatment will consist of daily self-administration of three routes; Nitric Oxide Gargle (NOG) every morning, Nitric Oxide Nasophyaryngeal Irrigation (NONI) every evening, and Nitric Oxide Nasal Spray (NONS) up to 5 times per day.~Any participants enrolled in the Prevention study who meet the criteria for the sub study will roll over into the Treatment Sub-Study but must remain in their randomly assigned group.
Study NCT04737304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEN2293 (0.25% or 1.0% w/w) or matching placebo
Description: BEN2293 and placebo will be administered as a topical ointment. Both ointments contain the same excipients; placebo ointment has been manufactured in the same way except for the addition of 0.25% and 1.0% (w/w) BEN2293.
Study NCT04737304 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BEN2293 (0.25% or 1.0% w/w) or matching placebo
Description: BEN2293 and placebo will be administered as a topical ointment. Both ointments contain the same excipients; placebo ointment has been manufactured in the same way except for the addition of 0.25% and 1.0% (w/w) BEN2293.
Study NCT00655200 — intervention group
Intervention type: DRUG
Intervention: insulin detemir
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study NCT00392769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Initial Dose = 400 mg/m\^2 IV Over 120 Minutes, Followed by Weekly Infusions at 250 mg/m\^2 IV Over 60 Minutes.
Study NCT00686686 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Intravenous infliximab 5 mg/kg given over a 2-hour period at Weeks 0, 2, and 6 and possibly at week 12.
Study NCT03644472 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nitrate rich beetroot juice
Description: This beverage contains 0.3 g of inorganic nitrate per 70 ml container, and is bottled and supplied by James White Drinks (UK).
Study NCT03644472 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nitrate depleted beetroot juice
Description: This beverage is identical in look and taste to the Beet-It organic shot, but has the nitrate removed. It is also bottled and supplied by James White Drinks (UK).
Study NCT02566369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD5789 (trifarotene) 50μg/g cream
Description: CD5789 (trifarotene) 50µg/g cream applied once daily for 12 weeks.
Study NCT02566369 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Description: Placebo cream applied once daily for 12 weeks
Study NCT03644511 — intervention group
Intervention type: DRUG
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: Prescribed by physician.
Study NCT03644511 — intervention group
Intervention type: DRUG
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Prescribed by physician.
Study NCT02991976 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen concentration
Description: Shunting, raising concentration of O2 because of improving regional cerebral oxygen saturation (rSO2), keeping blood pressure above 120-130 mmHg, positive end expiratory pressure (PEEP)
Study NCT02900040 — intervention group
Intervention type: OTHER
Intervention: kidney transplantation
Study NCT01564576 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Profound neuromuscular blockade (Rocuronium, Rocuronium bromide, sugammadex, Bridion)
Description: Rocuronium dose will be adjusted to maintain a depth of NMB of zero response to train of four and a post tetanic count of no more than 10 responses. At the end of surgery patients will receive a single bolus dose of 4 mg/kg sugammadex according to ideal body weight + 40%12. Extubation will be performed when train-of-four ratios ≥ 0.9.
Study NCT01564576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Profound neuromuscular blockade (Rocuronium, Rocuronium bromide, sugammadex, Bridion)
Description: Rocuronium dose will be adjusted to maintain a depth of NMB of zero response to train of four and a post tetanic count of no more than 10 responses. At the end of surgery patients will receive a single bolus dose of 4 mg/kg sugammadex according to ideal body weight + 40%12. Extubation will be performed when train-of-four ratios ≥ 0.9.
Study NCT00631943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin (Lyrica)
Description: Oral pregabalin (Lyrica) capsules, initial dose of 75 mg twice daily, which could be increased to 300 mg twice daily at the discretion of the investigator. Patients were treated for up to 21 days.
Study NCT03214666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTB-3550 TriKE® Phase I
Description: The 1st two patients will be assigned Dose Level 1. The study statistician will assign each new cohort of 2 patients to the most appropriate dose level based on updated toxicity probabilities.~* Dose Level 1 - 5 μg/kg/day~* Dose Level 2 - 10 μg/kg/day~* Dose Level 3 - 25 μg/kg/day~* Dose Level 4 - 50 μg/kg/day~* Dose Level 5 - 100 μg/kg/day~* Dose Level 6 - 150 μg/kg/day~* Dose Level 7 - 200 μg/kg/day
Study NCT03214666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTB-3550 TriKE® Phase II
Description: Patients will receive the maximum tolerated dose (MTD) established during Phase I with monitoring guidelines to stop the study early for excessive toxicity.
Study NCT02474069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Secukinumab
Study NCT02411890 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor canal block (active)
Description: adductor canal block: single injection, 0.5% levobupivacaine 15 ml with adrenaline 5 µg/ml, ultrasound guidance with nerve stimulator
Study NCT02411890 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral nerve block (active)
Description: femoral nerve block: single injection, 0.25% levobupivacaine 30 ml with adrenaline 5 µg/ml, ultrasound guidance with nerve stimulator
Study NCT02411890 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femoral nerve block (sham block)
Description: 30 mL of normal saline injected into absorbing cloth through stump needle at the inguinal area but not penetrating skin, ultrasound guidance and nerve stimulator with percutaneous electronic guidance to create quadriceps contraction before injection
Study NCT02411890 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adductor canal block (sham block)
Description: 30 mL of normal saline injected into absorbing cloth through stump needle at the midfemoral area but not penetrating skin, ultrasound guidance and nerve stimulator with percutaneous electronic guidance without muscle contraction
Study NCT04578236 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Aerosolized 13 cis retinoic acid plus Inhalation administration by nebulization captopril 25mg
Description: Infected patients will receive aerosolized 13 cis retinoic acid in gradual one dose per day increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days plus Inhalation administration by nebulization captopril 25mg for 14 days
Study NCT04578236 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Drug: Standard treatment Standard treatment
Description: Drug: Standard treatment Standard treatment is according to the protocol of treatment of 2019-nCoV infection
Study NCT03336112 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioral therapy (I-CBT)
Description: The intervention (I-CBT) will consist of 5 weeks of Internet-delivered cognitive behavioral therapy using three main parts. The first is psychoeducation that aims to educate the patients about chest pain and other causes than the cardiac ones. The other part concerns avoidance and exposure. This includes exposing the patients to physical activities that patients perceive as a threat to the heart. The third part contains awareness (mindfulness) training to teach the patients to have contact with the present moment despite chest pain and not trying to avoid it.
Study NCT03336112 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Information program
Description: Information program delivered by the Internet during 5 weeks.
Study NCT02003599 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser therapy
Description: The low level laser therapy used in this trial will be Photon Lase III (DMC, approved by ANVISA for medicinal purposes). This InGaAIP laser emits a pulsed 660 nanometer beam with an average output of 80 milliwatts and the average energy density delivered to the breast will be 3 J/cm2.
Study NCT02003599 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In the control group, 26 patients will be submitted to a laser, but the laser will be disabled without affecting its apparent function , five days a week before radiotherapy .
Study NCT00299169 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: N of 1 Trials
Description: N of 1 Trials of statin therapy
Study NCT00299169 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: N of 1 Trials
Description: N of 1 Trials of statin therapy
Study NCT05454917 — intervention group
Intervention type: DEVICE
Intervention: Measure of ventilation/perfusion (V/Q) mismatch using Beacon ALPE (Automatic Lung Paramether Estimator)
Description: Evaluation of intraoperative V/Q mismatch using the Beacon ALPE during anesthesia.
Study NCT04310371 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3-month lifestyle intervention
Description: Adolescents from the intervention group will be enrolled at the obesity center for the whole school year (i.e., 10 months). The physical activity program consists of two training sessions (aerobic and resistance training) per week.~There will be two measurement time: one at baseline (Day 0) and one at three months after the beginning of the lifestyle intervention (M3). The controls will be evaluated at baseline only.
Study NCT01995188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 15 milligrams per kilogram (mg/kg) administered via IV infusion on Day 1 of each 21-day cycle until disease progression or death, whichever occurs first.
Study NCT01995188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin fixed dose of AUC=6 mg/mL\*min administered by IV infusion on Day 1 of each 21-day dose escalation and expansion cycles. Carboplatin will be administered for a maximum of 6 cycles or until disease progression or unacceptable toxicity, whichever is first.
Study NCT01995188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNIB0600A
Description: DNIB0600A at an initial dose of 1.2 mg/kg will be administered via IV infusion further following a dose-escalation until DLT under consultation of the investigator on Day 1 of 21 day dose-escalation cycle. RP2D will be administered further in dose-expansion for until disease progression or death, whichever occurs first.
Study NCT03832049 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 9-valent human papillomavirus vaccine (Gardasil 9) - 3 doses
Description: 0.5mL intramuscular dose - 3 doses (0, 2 and 6 months)
Study NCT03832049 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 9-valent human papillomavirus vaccine (Gardasil 9) - 2 doses
Description: 0.5mL intramuscular dose - 2 doses (0 and 6 months)
Study NCT03832049 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 9-valent human papillomavirus vaccine (Gardasil 9) - 1 dose
Description: 0.5mL intramuscular dose - 1 doses (0 months)
Study NCT01538667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (Cipro Inhale, BAYQ3939)
Description: 50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by healthy subjects
Study NCT01538667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (Cipro Inhale, BAYQ3939)
Description: 50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by healthy subjects under charcoal block
Study NCT01538667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (Cipro Inhale, BAYQ3939)
Description: 50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by COPD patients
Study NCT01538667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (Cipro Inhale, BAYQ3939)
Description: 50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by bronchiectasis patients
Study NCT02575690 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Spirulina
Description: Individuals receive 2 g of spirulina daily, for 3 months.
Study NCT02575690 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Individuals receive a placebo daily, for 3 months.
Study NCT05008406 — intervention group
Intervention type: OTHER
Intervention: Satisfaction
Description: Students Satisfaction
Study NCT00330967 — intervention group
Intervention type: DRUG
Intervention: 20% Intralipid
Description: lipid infusion
Study NCT02439502 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fuse® system
Description: Fuse® system will be used to perform gastro and endoscopic diagnostic procedures for upper and lower GI tract.
Study NCT02236936 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard care of parenteral nutrition
Description: Standard treatment according to the discretion of the center, any required nutritional support (enteral tube feeding by nasogastric tube or percutaneous endoscopic gastrostomy) when considered necessary is allowed
Study NCT02236936 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Parenteral over night nutrition
Description: Patients in interventional Arm B will receive parenteral overnight nutrition with ZentroOLIMEL® 5.7% with electrolytes, vitamins (Cernevit®) and micronutrients (Addel Trace® or Nutryelt®) starting with 15 ml/kg body weight/day. In case of weight loss of more than 5%, dose of ZentroOLIMEL® has to be increased up to 25 ml/kg/body weight/day.
Study NCT02236936 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Weekly during radiotherapy; not given if cisplatin is given during radiotherapy~Cetuximab 400 mg/m2 (saturation) Cetuximab 250mg/m2 (during radiotherapy; in total 7x)
Study NCT02236936 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Weekly during radiotherapy; not given if cisplatin is given during radiotherapy~Cetuximab 400 mg/m2 (saturation) Cetuximab 250mg/m2 (during radiotherapy; in total 7x)
Study NCT02236936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin total dose of >200 mg administered weekly (40 mg/m2/week) or every three weeks (100 mg/m2 every three weeks) according to local standard; not given in combination with cetuximab
Study NCT02236936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin total dose of >200 mg administered weekly (40 mg/m2/week) or every three weeks (100 mg/m2 every three weeks) according to local standard; not given in combination with cetuximab
Study NCT02236936 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: 70 Gy / 5 fractions per week, over 7 weeks
Study NCT02236936 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 70 Gy / 5 fractions per week, over 7 weeks
Study NCT01419288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill Training
Description: The program requires volunteer participants to attend 15 sessions over 10 to 12 weeks with a total time commitment of 13.5 hours. There is an initial testing session that includes an assessment of the participant's legs, balance, and walking abilities. The entire program includes 12 treadmill training visits that take place three times per week for four weeks, a post-training testing session one week after completion of the training, and a follow-up testing session four weeks after completion of the training.
Study NCT01419288 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill Training
Description: The program requires volunteer participants to attend 15 sessions over 10 to 12 weeks with a total time commitment of 13.5 hours. There is an initial testing session that includes an assessment of the participant's legs, balance, and walking abilities. The entire program includes 12 treadmill training visits that take place three times per week for four weeks, a post-training testing session one week after completion of the training, and a follow-up testing session four weeks after completion of the training.
Study NCT00922012 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromagnetic Stimulation Therapy
Description: Electromagnetic Stimulation Therapy for 24 weeks
Study NCT01098513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572 formulation AP
Description: GSK1349572 50 mg single dose fasted.
Study NCT01098513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572 formulation AW
Description: GSK1349572 formulation AW 50 mg single dose in Part A and 75 to 200 mg fasted or with moderate or high fat meal in Part B.
Study NCT01098513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572 formulation AX
Description: GSK1349572 formulation AX 50 mg in Part A and 75-200 mg fasted or with a moderate or high fat meal in Part B
Study NCT01632618 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trunk Muscle Training+NMES
Description: Progressive exercise program for the stabilizing muscles of the trunk, as well as neuromuscular electrical stimulation to the lumbar paraspinals
Study NCT01632618 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Passive control intervention
Description: Passive physical therapy approach to low back pain
Study NCT03962504 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: trauma-focused treatment
Description: cognitive behavioral treatment for posttraumatic stress disorder that consists of exposure to the trauma memory.
Study NCT03962504 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: trauma-focused treatment
Description: cognitive behavioral treatment for posttraumatic stress disorder that consists of exposure to the trauma memory.
Study NCT00845117 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cultivated limbal stem cell graft transplantation
Description: A limbal biopsy taken from the contralateral good eye in cases of unilateral disease or from a living related or cadaveric donor in cases of bilateral disease. The limbal stem cells from the biopsy are cultivated until a sheet of cells measuring approximately 12mm in diameter is obtained. This is then ready for transplantation onto the diseased eye.
Study NCT00035932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir + ritonavir + tenofovir + nucleoside
Description: Active Comparator, Capsules, tablets, Oral
Study NCT00035932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir + saquinavir + tenofovir + nucleoside
Description: Active Comparator, Capsules, tablets, Oral